David Naveh is a biotechnology expert with an extensive career spanning manufacturing technologies, process development of biological products, formulation development, preclinical and clinical development, and licensure. Over the course of 15 years and a $700M investment, David led the transformation of Bayer’s blood fractionation factory in Berkeley CA into Bayer AG’s Biotech site, culminating in his role as Vice President and Chief Technology Officer of Bayer Biologics Worldwide.
David has played a pivotal role in the market introductions of biologics such as Intron, Remicade, and Kogenate, each of which achieved peak sales exceeding $1 billion.
His board experience includes BOD positions with Titan Biotech, Discovery Labs (DSCO), MountainView Pharmaceuticals (MVP), Immune Therapeutics (IMNP), Glycominds, Philogene, Pangene Corp (PGC), and intensive advisory roles with pharmaceutical companies such as Teva and Compugen. He was also an active board member of Bionovo (BNVO), a botanical company focused on women’s healthcare, where he provided guidance on production, regulatory activities, and FDA interactions.
Later, David founded Hemogem - the GEM of Hemostasis a drug development company focused on bleeding and clotting . He led a team of eight employees and a network of 10-60 subcontractors. Under his leadership, Hemogem secured multiple international agreements with companies such as Alcon (USA), LFB (France), Chemo España (Spain), and Advantech (Brazil).
Born and raised in Haifa, Israel, David served as an officer in the Israeli Defense Forces during the Yom Kippur War. He holds a degree in Food Engineering from the Technion and earned a PhD and an MBA from the University of Minnesota, MPLS , in the NASA Space Science center where he developed for NASA Biochemical Engineerng / Food Science models related to Spaceships .As an Assistant Professor tenure track at the University of Wisconsin-Madison, he taught courses on Thermodynamics of Biological Products and the Physical Chemistry of Foods. David has authored 35 publications and holds 14 patents.
